Among these, 77 are approved for several indications associated with human inflammatory diseases, including a current treatment for Crohn’s disease (e.g., Natalizumab®, targeting ITGB1; Fig. 5e), an anti-inflammatory drug for IBD treatment (e.g., prednisone, targeting ITGB2; Fig. 5e), and other target genes/proteins with high centrality in the interaction network (e.g., Hydrocortisone targeting ITGAM; Fig. 5e). This evidence concerns the gene ITGB1 and inflammatory bowel disease.